Evidence map›Paper›PMID 41266898›Full record

ArticleAnnals of hematology2025

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study.

Yuqing Tu, Lingyi Yang, Yaxin Cheng, Yanming Zhang, Yinghao Lu, Shushu Xu, Xiaoli Li, Mimi Xu, Mengqi Xiang, Yi Fan and 14 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yuqing Tu *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Lingyi Yang *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Yaxin Cheng *Department of Hematology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Lujiang Road 17, Hefei, 230001, China.
Yanming Zhang *Department of Hematology, Huai'an Second People's Hospital, Huai'an Hospital Affiliated to Xuzhou Medical University, Huai'an, 223001, China.
Yinghao Lu *Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550000, China.
Shushu Xu *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Xiaoli LiDepartment of Hematology, Soochow Hopes Hematonosis hospital, Suzhou, 215006, China.
Mimi XuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Mengqi XiangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Yi FanNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Yuhua RuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Yang XuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Feng ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Xiaojin WuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Yulian ZhengDepartment of Hematology, Soochow Hopes Hematonosis hospital, Suzhou, 215006, China.
Fei LiDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Yue HanNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Xiaowen TangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Huiying QiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Miao MiaoNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China.
Ye ZhaoNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China. mutation@163.com.
Xiaoyu ZhuDepartment of Hematology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Lujiang Road 17, Hefei, 230001, China. xiaoyuz@ustc.edu.cn.
Depei WuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China. wudepei@suda.edu.cn.
Jia ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou, 215006, China. chenjia@suda.edu.cn.

Funding

Jiangsu Provincial Medical Innovation Center CXZX202201National Key Research and Development Program of China 2022YFC2502700National Natural Science Foundation of China 82200237National Natural Science Foundation of China 82330008National Natural Science Foundation of China 82370215Suzhou Science and Technology Program Project SKY2023047
6 · The paper itself

Abstract

Chronic graft-versus-host disease (cGVHD) is a major complication for long-term survivors after hematopoietic cell transplantation (HCT). Bronchiolitis obliterans syndrome (BOS) is the crucial manifestation of lung cGVHD. Ruxolitinib has been approved by the Food and Drug Administration (FDA) for cGVHD treatment, but the response for BOS has not been sufficiently evaluated. We conducted a multicenter study involving 125 patients diagnosed with BOS post-HCT who received second-line therapies, including 77 patients treated with ruxolitinib (ruxolitinib group) and 48 patients with non-ruxolitinib therapies (control group). The primary endpoint was progression of BOS. By the third month, 18.2% of patients in the ruxolitinib group progressed, versus 43.8% in the control group (p = 0.001). The 2-year overall survival (OS) was 73.2% (95%CI 63.5%-84.5%) for the ruxolitinib group versus 60.2% (95%CI 47.4%-76.6%) for the control group (p = 0.012). The BOS-progression-free survival (BOS-PFS) was 69.0% (95%CI 59.1%-80.5%) versus 51.2% (95%CI 38.7%-67.7%, p = 0.011). Early switch to second-line therapy for BOS independently favored lower progression incidence (OR = 0.203, [95%CI 0.070-0.585], p = 0.003). Additionally, we observed that ruxolitinib was well-tolerated during the treatment of BOS. In conclusion, our findings indicated that ruxolitinib is an effective and safe second-line option for BOS.

Indexed as

Bronchiolitis ObliteransHematopoietic Stem Cell TransplantationPyrazolesAdolescentAdultAgedBronchiolitis Obliterans SyndromeFemaleGraft vs Host DiseaseHumansMaleMiddle AgedNitrilesPyrimidinesRetrospective StudiesSurvival RateNitrilesPyrazolesPyrimidinesruxolitinibAllogeneic hematopoietic cell transplantationBronchiolitis obliterans syndromeChronic graft-versus-host diseaseRuxolitinib

Identifiers

PMID41266898
PMCPMC12764499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.